Does eptinezumab plus education reduce migraine days in chronic migraine patients who overuse medication?
Chronic migraine often involves medication overuse, which makes the condition harder to treat. A specific study looked at whether adding eptinezumab, a CGRP antibody, to a short educational program helps reduce the number of migraine days in these patients. The research shows that this combination approach does lower migraine frequency compared to placebo.
What the research says
Other sources provide context on chronic migraine treatment. One study noted that combining preventive treatments with different physiological targets may yield greater benefit than using a single treatment alone 1. Another study found that eptinezumab can reduce pain intensity and symptoms like photophobia and phonophobia during an ongoing migraine attack 2. Research using brain imaging also shows that chronic migraine is associated with reduced brain entropy, a measure of neural complexity, which correlates with greater headache frequency 3.
What to ask your doctor
- Does my current treatment plan address medication overuse alongside my chronic migraine?
- Is eptinezumab combined with a brief educational intervention an option for me?
- How will we measure if my monthly migraine days decrease after starting this treatment?
- What are the common side effects I should watch for with eptinezumab?
- How does my specific medication history affect my eligibility for CGRP antibody therapy?
This question is drawn from common patient questions about Pulmonology & Critical Care and answered using cited medical research. We do not provide individualized advice.